Key result
FLOT1 protein was significantly overexpressed in transitional cell carcinoma tissues (92.9%) compared to normal urothelial tissues (12.0%), and high expression correlated with tumor size, grade, stage, and recurrence.
Observational (n=298)
No
FLOT1 is overexpressed in bladder transitional cell carcinoma and promotes tumor cell proliferation, adhesion, migration, and invasion, suggesting it may be a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
FLOT1 may mark aggressive bladder tumors; hypothesis-generating for targeted therapy but should not change practice.
Flotillin-1 (FLOT1) is known to have a role in tumorigenesis; however, the effect of FLOT1 on proliferation and recurrence of human transitional cell carcinoma (TCC) is unclear. Samples from 156 TCC patients and 142 patients undergoing open bladder surgery for indications other than TCC were used in the present study. FLOT1 protein expression was determined by immunohistochemistry and western blot analysis, and mRNA expression was detected by RT-PCR and real-time PCR. A FLOT1-expressing pcDEF3 vector was stably transfected into 4 TCC cell lines and FLOT1 expression was decreased by RNAi. Proliferative analysis of TCC cells was detected by the WST-1 assay and a xenograft model using BALB/C nude mice. The association between FLOT1 expression and TCC recurrence was also analyzed by adhesion, migration and invasion assays. FLOT1 expression in TCC was significantly overexpressed compared to normal urothelial tissue, and the level of FLOT1 expression was significantly correlated with tumor size, pathologic grade, clinical stage and recurrence. In addition, FLOT1 significantly increased the proliferative ability of TCC cells in vitro and in vivo. TCC cells with a high level of FLOT1 expression exhibited a higher level of adhesion, migration and invasion. FLOT1 expression was shown to be upregulated in human TCC. These findings suggest that FLOT1 plays an important role in the proliferation and recurrence of TCC and that silencing FLOT1 expression might be a novel therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2014) conducted an observational in Bladder transitional cell carcinoma (n=298). FLOT1 overexpression vs. Normal urothelial tissue was evaluated on FLOT1 protein expression positivity (p=<0.05). FLOT1 protein was significantly overexpressed in transitional cell carcinoma tissues (92.9%) compared to normal urothelial tissues (12.0%), and high expression correlated with tumor size, grade, stage, and recurrence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: